<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03506815</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT03506815</nct_id>
  </id_info>
  <brief_title>Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines</brief_title>
  <acronym>TRIM-Line</acronym>
  <official_title>A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Investigating Primary Thromboprophylaxis With Rivaroxaban in Patients With Malignancy and Central Venous Catheters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Queen Elizabeth II Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of Pilot Trial To determine the feasibility of conducting a multicentre randomized&#xD;
      open label controlled trial evaluating the use of prophylactic dose rivaroxaban to prevent&#xD;
      central venous catheter (CVC) associated venous thromboembolism(VTE) among cancer patients.&#xD;
&#xD;
      Hypothesis: treatment with low dose rivaroxaban (10mg) will reduce the incidence of upper&#xD;
      extremity venous thrombosis in a high risk population with cancer and CVC.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      This is a pilot interventional study to be conducted at 3 Canadian Centres. The Ottawa&#xD;
      Hospital, QEII Health Science Centre and University of Alberta Hospital.&#xD;
&#xD;
      It is an open label randomized controlled trial.&#xD;
&#xD;
      Consenting participants, meeting eligibility criteria will be randomized at the time of&#xD;
      enrollment to one of two groups.&#xD;
&#xD;
      Rivaroxaban 10mg po daily x 90 (+/- 3 ) days OR Standard of Care&#xD;
&#xD;
      Participants in the treatment arm will have study drug dispensed at Day 1 and take medication&#xD;
      for 90 days. Follow up visits (in person or phone) will occur at Day 30 (+/- 3 days) and Day&#xD;
      90 (+/- 3 days) month and 3 months post enrollment. Overall, participants will be followed&#xD;
      for 3 months. Adverse events will be collected for the first 90 days.&#xD;
&#xD;
      Outcomes The primary feasibility outcome for the pilot study is the number of participants&#xD;
      recruited per centre per month. We will obtain baseline details of the patient's type,&#xD;
      location and treatment of cancer, comorbidities and medications. Secondary feasibility&#xD;
      outcomes of the pilot study will include, consent rates, loss to follow up, adherence to&#xD;
      therapy defining 80% or greater medication taken as having good adherence to study drug,&#xD;
      proportion of screened patients who meet eligibility criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Actual">June 14, 2020</completion_date>
  <primary_completion_date type="Actual">May 14, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Pilot Trial comparing two groups - Rivaroxaban 10mg po daily x90 days vs standard of care(usual treatment)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pilot Feasibility Outcome- Enrolment</measure>
    <time_frame>6 months</time_frame>
    <description>Number of Participants recruited per centre per month</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consent rate</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of approached patients who consent to enter study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss to follow up</measure>
    <time_frame>6 months</time_frame>
    <description>During the 90 (+/-3) days of the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to Therapy</measure>
    <time_frame>6 months</time_frame>
    <description>Good adherence defined as 80% or greater study medication taken</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of screened patients which meet eligibility criteria</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Upper Extremity Deep Vein Thrombosis</condition>
  <condition>Central Venous Catheter Thrombosis</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban Thromboprophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban 10 mg po daily for 90 days(+/- 3 days). After the Day - 90 follow up, the study treatment will be discontinued and subsequent treatment will be at the discretion of the attending physician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No rivaroxaban prophylaxis. Management will be at the discretion of the attending physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 10 MG</intervention_name>
    <description>Rivaroxaban 10mg po daily x 90 (+/- 3 days)</description>
    <arm_group_label>Rivaroxaban Thromboprophylaxis</arm_group_label>
    <other_name>Xarelto 10mg tablet po daily</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1.Patients 18 years of age or older with a new or existing diagnosis of cancer with a CVC&#xD;
        inserted within the last 72 hours.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. CVC in place for &gt;72 hours&#xD;
&#xD;
          2. Patient requires anticoagulation for other indication&#xD;
&#xD;
          3. Concomitant use of dual antiplatelet therapy&#xD;
&#xD;
          4. Prior VTE&#xD;
&#xD;
          5. Major bleeding event in the last 6 weeks&#xD;
&#xD;
          6. Patient on concomitant medication with known interaction with rivaroxaban (eg. CYP3A4&#xD;
             inhibitor)&#xD;
&#xD;
          7. Pregnancy (documentation of use of effective contraception if sexually active or&#xD;
             negative B-Hcg required)&#xD;
&#xD;
          8. Known renal failure, based on Creatinine clearance &lt;30 mL/min (Cockcroft-Gault) (in&#xD;
             the previous 3 months)&#xD;
&#xD;
          9. Documented severe liver disease (eg. acute clinical hepatitis, chronic active&#xD;
             hepatitis, cirrhosis or ALT &gt;3ULN) ( in the previous 3 months)&#xD;
&#xD;
         10. Known thrombocytopenia &lt; 50x 109/L (in the previous 3 months)&#xD;
&#xD;
         11. Allergy to rivaroxaban&#xD;
&#xD;
         12. Life expectancy &lt;6 months&#xD;
&#xD;
         13. History of condition at increased bleeding risk including, but not limited to:&#xD;
&#xD;
               1. Major surgical procedure or trauma within 30 days before the randomization visit&#xD;
&#xD;
               2. Clinically significant gastrointestinal bleeding within 6 months before the&#xD;
                  randomization visit&#xD;
&#xD;
               3. History of intracranial, intraocular, spinal, or atraumatic intra-articular&#xD;
                  bleeding&#xD;
&#xD;
               4. Chronic hemorrhagic disorder&#xD;
&#xD;
               5. Known intracranial neoplasm, arteriovenous malformation, or aneurysm&#xD;
&#xD;
               6. Sustained uncontrolled hypertension: systolic blood pressure ≥180 mmHg or&#xD;
                  diastolic blood pressure ≥100 mmHg&#xD;
&#xD;
         14. Primary malignancy diagnosis of basal cell or squamous cell carcinoma of the skin or&#xD;
             acute leukemia or myelodysplastic syndrome&#xD;
&#xD;
         15. Geographic inaccessibility&#xD;
&#xD;
         16. Refused or unable to obtain consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rick T Ikesaka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute / Division of Hematology- The Ottawa Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ottawa Hospital General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2018</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Upper Extremity Deep Vein Thrombosis</keyword>
  <keyword>Thromboprophylaxis</keyword>
  <keyword>Cancer</keyword>
  <keyword>Randomized Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Upper Extremity Deep Vein Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pilot Feasibility Study- no current plan to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

